Newspaper icon
The latest issue of Financial Standard now available as an e-newspaper
READ NOW

Search Results

Showing 1 - 6 of 6 results for "Opthea"

Regal profits rise 65%, Pacific Current reports $11.7m loss

ELIZA BAVIN  |  TUESDAY, 24 FEB 2026
... challenges, he was pleased with the end result. "Regal's hedge funds experienced a disappointing outcome from the investment in Opthea, which was written down to zero in March 2025. We are extremely grateful for the support we received from our clients ...

VG1 replaces investment manager, books massive loss

KARREN VERGARA  |  THURSDAY, 21 AUG 2025
... and oversight of the VG1 portfolio since June 2023," Jones said. VG1's FY25 performance was marred by biotech company Opthea, which was written down to zero after unsuccessful phase three clinical trials. "This was a disappointing outcome for VG1 ...

Regal writes off Opthea, FUM takes 8% hit

KARREN VERGARA  |  THURSDAY, 10 APR 2025
Regal Partners has written off its entire investment in Opthea, which contributed to funds under management (FUM) taking an 8.3% hit in the March 2025 quarter. Regal ended up with $16.5 billion as total FUM suffered a $540 million loss stemming from ...

Hearts & Minds revalues position amid Opthea fallout

JAMIE WILLIAMSON  |  WEDNESDAY, 26 MAR 2025
Following Regal's lead, Hearts & Minds Investments has now also revalued its holding in Opthea following its failed clinical trials. Yesterday, Regal announced it had significantly devalued its holdings in the biopharmaceutical company after it ...

Regal slashes holdings in Opthea over insolvency concerns

KARREN VERGARA  |  TUESDAY, 25 MAR 2025
Regal Asian Investments (ASX:RG8) has significantly devalued its holdings in biopharmaceutical company Opthea after the latter flagged insolvency concerns amid the failure of a major clinical trial. RG8 has been forced to drop Opthea's value to ...

Regal Atlantic fund perks up in April

KANIKA SOOD  |  THURSDAY, 14 MAY 2020
... back of initial data relating to a COVID-19 patient trial. Two other healthcare stocks, Medical Developments (up 42%) and Opthea (up 32%) were other positive contributors. Its detractors for the month came from its short book, especially cyclical and ...
PAGE:
1